KRAS and lung adenocarcinoma: Zhang et al. analyzed EGFR, KRAS, ALK, HER2, and BRAF mutation in 349 Chinese never-smoker females with lung adenocarcinoma and discovered mutation rates of 76%, 5%, 4%, 2%, and 1% for EGFR, HER2, ALK, KRAS, and HER2, respectively, while only 12% of cases harbored no detected mutation [25].